Long-Term Blood Pressure Control: What Can We Do?

References

• . Chobanian AV, Bakris GL, Black HR, ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560–2572
   PubMed Web of Science ®Google Scholar
• . Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903–1913
   PubMed Web of Science ®Google Scholar
• . ; Writing Group MembersLloyd-Jones D, Adams RJ, Brown TM, . Heart disease and stroke statistics—2010 update: a report from the American Heart Association. Circulation. 2010;121(7):e46–e215
   Google Scholar
• . Ong KL, Cheung BM, Man YB, Lau CP, Lam KS. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999–2004. Hypertension. 2007;49(1):69–75
   PubMed Web of Science ®Google Scholar
• . Steinberg BA, Bhatt DL, Mehta S, . Nine-year trends in achievement of risk factor goals in the US and European outpatients with cardiovascular disease. Am Heart J. 2008;156(4):719–727
   PubMed Web of Science ®Google Scholar
• . Wolf-Maier K, Cooper RS, Kramer H, . Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension. 2004;43(1):10–17
   PubMed Web of Science ®Google Scholar
• . Borzecki AM, Oliveria SA, Berlowitz DR. Barriers to hypertension control. Am Heart J. 2005;149(5):785–794
   PubMedGoogle Scholar
• . Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487–497
   PubMed Web of Science ®Google Scholar
• . Muszbek N, Brixner D, Benedict A, . The economic consequences of noncompliance in cardiovascular disease and related conditions: a literature review. Int J Clin Pract. 2008;62(2):338–351
   PubMed Web of Science ®Google Scholar
• . Erkens JA, Panneman MJ, Klungel OH, van den Boom G, Prescott MF, Herings RM. Differences in antihypertensive drug persistence associated with drug class and gender: a PHARMO study. Pharmacoepidemiol Drug Saf. 2005;14(11):795–803
   Google Scholar
• . Siiskonen SJ, Breekveldt-Postma NS, Vincze G, Khan ZM, Erkens JA, Herings RM. Higher persistence with valsartan compared with enalapril in daily practice. Vasc Health Risk Manage. 2007;3(6):1039–1044
   PubMedGoogle Scholar
• . Materson BJ, Reda DJ, Cushman WC, . Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med. 1993;328(13):914–921
   PubMed Web of Science ®Google Scholar
• . Mancia G, DeBaker G, Dominiczak A, ; ESH-ESC Task Force on the Management of Arterial Hypertension. 2007 ESH-ESC practice guidelines for the management of arterial hypertension. J Hypertens. 2007;25(9):1751–1762
   PubMed Web of Science ®Google Scholar
• . Chrysant SG. Fixed low-dose drug combination for the treatment of hypertension. Arch Fam Med. 1998;7(4):370–376
   Google Scholar
• . Messerli FH. Combination therapy in hypertension. J Hum Hypertens. 1992;6( suppl 2):19S–21S
   PubMed Web of Science ®Google Scholar
• . Epstein M, Bakris G. Newer approaches to antihypertensive therapy. Use of fixed-dose combination therapy. Arch Intern Med. 1996;156(17):1969–1978
   PubMedGoogle Scholar
• . Sica DA. Fixed-dose combination anti-hypertensive drugs. Do they have a role in rational therapy? Drugs. 1994;48(1):16–24
   Google Scholar
• . Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120(8):713–719
   PubMed Web of Science ®Google Scholar
• . Yusuf S, Teo KK, Pogue J, ; ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547–1559
   PubMed Web of Science ®Google Scholar
• . Cohn JN, Goldman JM. Establishing a new option for target-organ protection: rationale for ARB plus ACE inhibitor combination therapy. Am J Hypertens. 2008;21(3):248–256
   PubMed Web of Science ®Google Scholar
• . Mason RP. A rationale for combination therapy in risk factor management: a mechanistic perspective. Am J Med. 2005;118( suppl 12A):54–61
   Google Scholar
• . Siragy HM, Xue C, Webb RL. Beneficial effects of combined benazepril-amlodipine on cardiac nitric oxide, cGMP, and TNF-alpha production after cardiac ischemia. J Cardiovasc Pharmacol. 2006;47(5):636–642
   PubMed Web of Science ®Google Scholar
• . Zhang X, Hintze TH. Amlodipine releases nitric oxide from canine coronary microvessels: an unexpected mechanism of action of a calcium channel-blocking agent. Circulation. 1998;97(6):576–580
   PubMed Web of Science ®Google Scholar
• . Neutel JM, Smith DH, Weber MA. Effect of antihypertensive monotherapy and combination therapy on arterial distensibility and left ventricular mass. Am J Hypertens. 2004;17(1):37–42
   Web of Science ®Google Scholar
• . Jamerson K, Weber MA, Bakris GL, ; ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417–2428
   PubMed Web of Science ®Google Scholar
• . ; Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) InvestigatorsYusuf S, Teo K, Anderson C, . Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372(9644):1174–1183
   PubMed Web of Science ®Google Scholar
• . Chrysant SG. Amlodipine/ARB fixed-dose combinations for the treatment of hypertension: focus on amlodipine/olmesartan combination. Drugs Today (Barc). 2008;44(6):443–453
   Google Scholar
• . Braun N, Ulmer HJ, Ansari A, Handrock R, Klebs S. Efficacy and safety of the single pill combination of amlodipine 10 mg plus valsartan 160 mg in hypertensive patients not controlled by amlodipine 10 mg plus olmesartan 20 mg in free combination. Curr Med Res Opin. 2009;25(2):421–430
   PubMed Web of Science ®Google Scholar
• . Littlejohn TW 3rd, Majul CR, Olvera R, ; study investigators. Telmisartan plus amlodipine in patients with moderate or severe hypertension: results from a subgroup analysis of a randomized, placebo-controlled, parallel-group, 4 × 4 factorial study. Postgrad Med. 2009;121(2):5–14
   PubMed Web of Science ®Google Scholar
• . Littlejohn T 3rd, Chrysant SG, Neutel J, ; study investigators. Combination of telmisartan with amlodipine provides an effective treatment option for elderly patients: sub-analysis from a factorial design study. Poster presented at: 24th Annual Scientific Meeting of the American Society of Hypertension; May 6–9, 2009; San Francisco, CA
   Google Scholar
• . Littlejohn T 3rd, Punzi H, Serfer G, ; study investigators. Efficacy of telmisartan in combination with amlodipine in hypertensive patients from Latin and North America: sub-analysis from a factorial design study. Poster presented at: 24th Annual Scientific Meeting of the American Society of Hypertension; May 6–9, 2009; San Francisco, CA
   Google Scholar
• . Littlejohn T 3rd, Punzi H, Webster D, ; study investigators. Telmisartan plus amlodipine combination is effective in both treatment-naïve and previously treated hypertensive patients: sub-analysis from a factorial design study. Poster presented at: 24th Annual Scientific Meeting of the American Society of Hypertension; May 6–9, 2009; San Francisco, CA
   Google Scholar
• . Littlejohn T 3rd, Graff A, Punzi H, ; study investigators. Efficacy of telmisartan in combination with amlodipine in hypertensive patients according to race: sub-analysis from a factorial design study. Poster presented at: 24th Annual Scientific Meeting of the American Society of Hypertension; May 6–9, 2009; San Francisco, CA
   Google Scholar
• . Littlejohn T 3rd, Guthrie R, Neutel J, ; study investigators. Telmisartan and amlodipine in combination are effective at lowering 24-hour BP in black and Latin American hypertensive patients: findings of an ABPM substudy. Poster presented at: 24th Annual Scientific Meeting of the American Society of Hypertension; May 6–9, 2009; San Francisco, CA
   Google Scholar
• . Littlejohn T 3rd, Chrysant SG, Webster D, ; study investigators. Efficacy of telmisartan in combination with amlodipine in obese hypertensive patients: sub-analysis from a factorial design study. Poster presented at: 24th Annual Scientific Meeting of the American Society of Hypertension; May 6–9, 2009; San Francisco, CA
   Google Scholar
• . Neutel JM. Prescribing patterns in hypertension: the emerging role of fixed dose combinations for attaining BP goals in hypertensive patients. Curr Med Res Opin. 2008;24(8):2389–2401
   PubMed Web of Science ®Google Scholar
• . Vawter L, Tong X, Gemilyan M, Yoon PW. Barriers to antihypertensive medication adherence among adults—United States, 2005. J Clin Hypertens (Greenwich). 2008;10(12):922–929
   Google Scholar
• . Burnier M, Brown RE, Ong SH, Keskinaslan A, Khan ZM. Issues in blood pressure control and the potential role of single-pill combination therapies. Int J Clin Pract. 2009;63(5):790–798
   Google Scholar
• . Feldman RD, Zou GY, Vandervoort MK, Wong CJ, Nelson SA, Feagan BG. A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension. 2009;53(4):646–653
   PubMed Web of Science ®Google Scholar
• . Dúsing R, Handrock R, Klebs S, Tousset E, Vrijens B. Impact of supportive measures on drug adherence in patients with essential hypertension treated with valsartan: the randomized, open-label, parallel group study VALIDATE. J Hypertens. 2009;27(4):894–901
   Google Scholar
• . Stankus V, Hemmelgarn B, Campbell NR, Chen G, McAlister FA, Tsuyuki RT. Reducing costs and improving hypertension management. Can J Clin Pharmacol. 2009;16(1):151e–155e
   PubMedGoogle Scholar
• . Moser M. From JNC1 to JNC7–what have we learned? Prog Cardiovasc Dis. 2006;48(5):303–315
   PubMed Web of Science ®Google Scholar
• . Julius S, Kjeldsen SE, Weber M, ; VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363(9426):2022–2031
   PubMed Web of Science ®Google Scholar
• . Krousel-Wood MA, Muntner P, Islam T, Morisky DE, Webber LS. Barriers to and determinants of medication adherence in hypertension management: perspective of the cohort study of medication adherence among older adults. Med Clin North Am. 2009;93(3):753–769
   Google Scholar